Discover
NUVB
Nuvation Bio Inc.
5.42
8400 x undefined
10900 x undefined
bid
ask
-
0.26
4.58%
9650 @ 06:12 AM
5.30 -0.12 (2.21%)
| Ytd | -39.51% | |
| 1y | 179.38% |
5.33
day range
5.92
1.90
52 week range
9.75
| Open | 5.68 | Prev Close | 5.68 | Low | 5.33 | High | 5.92 | Mkt Cap | 1.89B |
| Vol | 7.39M | Avg Vol | 5.45M | EPS | -0.43 | P/E | N/A | Forward P/E | -94.42 |
| Beta | 1.56 | Short Ratio | 10.53 | Inst. Own | 64.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-04 | 50-d Avg | 4.95 | 200-d Avg | 5.42 | 1yr Est | 12.33 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-04 | 2026-03 | 0.12 | 0.01 | -0.11 | -91.67% |
| 2026-03-02 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-11-03 | 2025-09 | 0 | N/A | 0.01 | 5.88% |
| 2025-11-03 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-07 | 2025-06 | 0 | N/A | N/A | N/A |
| 2025-08-07 | 2025-06 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-05 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-05-05 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-05-05 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-04-16 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-04-02 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-03-27 | Wedbush | Upgrade | Outperform | Outperform |
Profile
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-03 | CUI XIANGMIN | Director | 0.00 | Conversion of Exercise of derivative security |
| 2025-11-18 | HANLEY DAVID C | Chief Technology Officer | 24.00K | Sale |
| 2025-06-15 | HUNG DAVID T | Chief Executive Officer | 59.28M | Purchase |
| 2026-04-16 | LIU DONGFANG | Officer | 18.00K | Sale |
| 2026-02-26 | MAKUNJE MOSES | Officer | 68.14K | Stock Award(Grant) |
| 2026-06-22 | MARKEL STACY | Officer | 32.59K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR, LLC | 51.99M | 281.78M | 14.93% |
| 2026-03-30 | Decheng Capital LLC | 25.95M | 140.67M | 7.45% |
| 2026-03-30 | Blackrock Inc. | 25.10M | 136.04M | 7.21% |
| 2026-03-30 | Vanguard Capital Management LLC | 11.63M | 63.01M | 3.34% |
| 2026-03-30 | Omega Fund Management, Llc | 8.08M | 43.80M | 2.32% |
| 2026-03-30 | Laurion Capital Management, LP | 7.82M | 42.40M | 2.25% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 17.54M | 95.05M | 5.04% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 8.66M | 46.92M | 2.49% |
| 2026-04-29 | iShares Trust-iShares Russell 2000 ETF | 5.67M | 30.73M | 1.63% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 4.91M | 26.62M | 1.41% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 4.52M | 24.48M | 1.30% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 2.66M | 14.40M | 0.76% |